Ampio Pharmaceuticals (AMPE) Competitors $0.0006 0.00 (0.00%) As of 04/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock AMPE vs. CMRA, GNCAQ, GNCA, ARDS, STAB, EFTR, PXMD, ONCSQ, ATNFW, and LBPSWShould you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), PaxMedica (PXMD), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), and 4D pharma (LBPSW). These companies are all part of the "pharmaceutical products" industry. Ampio Pharmaceuticals vs. Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma eFFECTOR Therapeutics PaxMedica OncoSec Medical 180 Life Sciences 4D pharma Ampio Pharmaceuticals (NYSE:AMPE) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends. Which has more risk and volatility, AMPE or CMRA? Ampio Pharmaceuticals has a beta of 3.77, indicating that its stock price is 277% more volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Does the media refer more to AMPE or CMRA? In the previous week, Ampio Pharmaceuticals had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Ampio Pharmaceuticals and 0 mentions for Comera Life Sciences. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score. Company Overall Sentiment Ampio Pharmaceuticals Neutral Comera Life Sciences Neutral Which has stronger earnings and valuation, AMPE or CMRA? Ampio Pharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00Comera Life Sciences$1.00M0.01-$18MN/AN/A Do insiders and institutionals have more ownership in AMPE or CMRA? 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is AMPE or CMRA more profitable? Company Net Margins Return on Equity Return on Assets Ampio PharmaceuticalsN/A N/A N/A Comera Life Sciences N/A N/A N/A Does the MarketBeat Community favor AMPE or CMRA? Ampio Pharmaceuticals and Comera Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformAmpio PharmaceuticalsOutperform VotesNo VotesUnderperform Votes72100.00% Comera Life SciencesN/AN/A SummaryAmpio Pharmaceuticals beats Comera Life Sciences on 4 of the 6 factors compared between the two stocks. Remove Ads Get Ampio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart AMPE vs. The Competition Export to ExcelMetricAmpio PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1,000.00$6.80B$5.59B$19.64BDividend YieldN/A2.81%5.35%3.77%P/E Ratio0.007.2123.6633.46Price / SalesN/A205.96369.2126.71Price / CashN/A65.6738.1617.54Price / Book0.006.156.714.61Net Income-$8.63M$142.11M$3.20B$1.02B7 Day PerformanceN/A-6.02%-3.93%-0.86%1 Month PerformanceN/A-10.79%-0.55%-3.14%1 Year PerformanceN/A-12.47%9.21%5.48% Ampio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.9%$1,000.00N/A0.0020Analyst ForecastNews CoverageCMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/A$0.00+∞N/AN/A$6,000.00N/A0.0070Gap UpGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00N/A0.0020EFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+3,999,900.0%-100.0%$3,000.00$3.55M0.0010PXMDPaxMedicaN/A$0.00flatN/A-100.0%$2,000.00N/A0.002ONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040ATNFW180 Life SciencesN/A$0.01+6.1%N/A-14.6%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/A Remove Ads Related Companies and Tools Related Companies Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors eFFECTOR Therapeutics Competitors PaxMedica Competitors OncoSec Medical Competitors 180 Life Sciences Competitors 4D pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AMPE) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
